Seres Therapeutics Inc (NASDAQ:MCRB) – Equities research analysts at Cantor Fitzgerald issued their FY2019 earnings estimates for shares of Seres Therapeutics in a research note issued on Sunday. Cantor Fitzgerald analyst W. Tanner forecasts that the biotechnology company will post earnings of ($2.12) per share for the year.
Several other research analysts have also recently weighed in on the company. BidaskClub cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. Zacks Investment Research raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 7th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. Seres Therapeutics presently has an average rating of “Buy” and a consensus target price of $18.00.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.73) by $0.02. Seres Therapeutics had a negative return on equity of 103.46% and a negative net margin of 278.44%. The company had revenue of $3.06 million during the quarter, compared to analysts’ expectations of $3.00 million.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Voya Investment Management LLC purchased a new stake in shares of Seres Therapeutics during the second quarter valued at $114,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Seres Therapeutics during the third quarter valued at $170,000. Aperio Group LLC purchased a new stake in shares of Seres Therapeutics during the third quarter valued at $191,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Seres Therapeutics during the fourth quarter valued at $143,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Seres Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,270 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 2,410 shares during the last quarter. 81.43% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Research Analysts Issue Forecasts for Seres Therapeutics Inc’s FY2019 Earnings (MCRB)” was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3259770/research-analysts-issue-forecasts-for-seres-therapeutics-incs-fy2019-earnings-mcrb.html.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.